Cell therapies show real curative potential. However, recently published research suggests the industry still needs faster, more effective production methods to fulfil its potential. For one thing, turning candidate cell therapies into commercial products will require innovation in manufacturing systems according to a study by researchers at the US National Institutes of Health. The study – published in International Reviews of Immunology – looked at the use of engineering T cell therapies (including those based on CAR-T cells and TCR-T…
